KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)
Phase: Phase II-III clinical trials
Principal Investigator: Dott. Lo Russo Giuseppe
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: R-DXd (raludotatug deruxtecan)
I-DXd (ifinatamab deruxtecan)
Docetaxel
Pathologies: Lung cancer
ClinicalTrials.gov: Read more about clinical trials
Participants will be randomized into one of four groups:
- Group 1: will receive R-DXd (raludotatug deruxtecan)
- Group 2: will receive I-DXd 12mg/kg (ifinatamab deruxtecan)
- Group 3: will receive I-DXd 8 mg/Kg (ifinatamab deruxtecan)
- Group 4: will receive docetaxel
Last update: 20/04/2026